4.3 Article

Reproducible Evaluation of Diffusion MRI Features for Automatic Classification of Patients with Alzheimer's Disease

Journal

NEUROINFORMATICS
Volume 19, Issue 1, Pages 57-78

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12021-020-09469-5

Keywords

Classification; Machine learning; Reproducibility; Alzheimer's disease; Diffusion magnetic resonance imaging; DTI; Open-source

Funding

  1. program Investissements d'avenir [ANR-10-IAIHU06, ANR-11-IDEX-004, SU-16-R-EMR-16]
  2. European Union [666992, 720270]
  3. joint NSF/NIH/ANR program Collaborative Research in Computational Neuroscience (project HIPLAY7) [ANR-16-NEUC-0001-01]
  4. Agence Nationale de la Recherche (project PREVDEMALS) [ANR-14-CE15-0016-07]
  5. European Research Council [678304]
  6. Abeona Foundation (project Brain@Scale)
  7. French government under Agence Nationale de la Recherche as part of the Investissements d'avenir program [ANR-19-P3IA0001]
  8. China Scholarship Council (CSC)
  9. Contrat d'Interface Local from Assistance Publique-Hopitaux de Paris (APHP)
  10. People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant through the PRESTIGE programme [PCOFUND-GA2013-609102]
  11. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  12. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  13. National Institute on Aging
  14. National Institute of Biomedical Imaging and Bioengineering
  15. AbbVie
  16. Alzheimer's Association
  17. Alzheimer's Drug Discovery Foundation
  18. Araclon Biotech
  19. BioClinica, Inc.
  20. Biogen
  21. Bristol-Myers Squibb Company
  22. CereSpir, Inc.
  23. Cogstate
  24. Eisai Inc.
  25. Elan Pharmaceuticals, Inc.
  26. Eli Lilly and Company
  27. EuroImmun
  28. F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.
  29. Fujirebio
  30. GE Healthcare
  31. IXICO Ltd.
  32. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  33. Johnson & Johnson Pharmaceutical Research & Development LLC.
  34. Lumosity
  35. Lundbeck
  36. Merck Co., Inc.
  37. Meso Scale Diagnostics, LLC.
  38. NeuroRx Research
  39. Neurotrack Technologies
  40. Novartis Pharmaceuticals Corporation
  41. Pfizer Inc.
  42. Piramal Imaging
  43. Servier
  44. Takeda Pharmaceutical Company
  45. Transition Therapeutics
  46. Canadian Institutes of Health Research
  47. Agence Nationale de la Recherche (ANR) [ANR-14-CE15-0016, ANR-16-NEUC-0001] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

Diffusion MRI is commonly used to study white matter alterations and automatically classify Alzheimer's disease. However, comparing classification performance is challenging due to variations in components, while reproducibility is hindered by the lack of readily available components. By extending an open-source framework to diffusion MRI data, it was found that feature selection has a positive impact on classification results, voxel-wise features generally outperform regional features, and adjustments in smoothing and registration methods do not significantly affect classification results.
Diffusion MRI is the modality of choice to study alterations of white matter. In past years, various works have used diffusion MRI for automatic classification of Alzheimer's disease. However, classification performance obtained with different approaches is difficult to compare because of variations in components such as input data, participant selection, image preprocessing, feature extraction, feature rescaling (FR), feature selection (FS) and cross-validation (CV) procedures. Moreover, these studies are also difficult to reproduce because these different components are not readily available. In a previous work (Samper-Gonzalez et al.2018), we propose an open-source framework for the reproducible evaluation of AD classification from T1-weighted (T1w) MRI and PET data. In the present paper, we first extend this framework to diffusion MRI data. Specifically, we add: conversion of diffusion MRI ADNI data into the BIDS standard and pipelines for diffusion MRI preprocessing and feature extraction. We then apply the framework to compare different components. First, FS has a positive impact on classification results: highest balanced accuracy (BA) improved from 0.76 to 0.82 for task CN vs AD. Secondly, voxel-wise features generally gives better performance than regional features. Fractional anisotropy (FA) and mean diffusivity (MD) provided comparable results for voxel-wise features. Moreover, we observe that the poor performance obtained in tasks involving MCI were potentially caused by the small data samples, rather than by the data imbalance. Furthermore, no extensive classification difference exists for different degree of smoothing and registration methods. Besides, we demonstrate that using non-nested validation of FS leads to unreliable and over-optimistic results: 5% up to 40% relative increase in BA. Lastly, with proper FR and FS, the performance of diffusion MRI features is comparable to that of T1w MRI. All the code of the framework and the experiments are publicly available: general-purpose tools have been integrated into the Clinica software package (www.clinica.run) and the paper-specific code is available at: https://github.com/aramis-lab/AD-ML.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available